[Indoleamine 2, 3-dioxygenase activity during chemotherapy or trastuzumab therapy in patients with breast cancer].

Kenichi Sakurai, Shigeru Fujisaki, Saki Nagashima, Tetsuyo Maeda, Masahiko Shibata, Kenshi Gonda, Ryouichi Tomita, Shuhei Suzuki, Yukiko Hara, Katsuhisa Enomoto, Sadao Amano

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

We evaluated the significance of indoleamine 2, 3-dioxygenase (IDO) in breast cancer patients during chemotherapy or trastuzumab therapy. IDO activity can be measured by the tryptophan(Trp)/kynurenine(Kyn) ratio. Trp and Kyn were measured by high-performance liquid chromatography(HPLC). The correlations between the Trp/Kyn ratios in the chemotherapy group and the trastuzumab therapy group with respect to pre-chemotherapies or post-chemotherapies were studied. The Trp/Kyn ratio of the chemotherapy group in the post-epirubicin and cyclophosphamide(EC) chemotherapy phase and in the post-weekly paclitaxel(wPTX) chemotherapy phase was lower than that in the pre-chemotherapy phase. In addition, the Trp/Kyn ratio in the chemotherapy group was significantly lower than that in the hormone therapy group in the post-EC chemotherapy phase and in the post-wPTX chemotherapy phase. There were no significant changes in the Trp/Kyn ratio in the trastuzumab therapy group in each phase. These results suggest that trastuzumab therapy may be less invasive than chemotherapy for breast cancer patients.

Original languageEnglish
Pages (from-to)1791-1793
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number12
Publication statusPublished - Nov 2012

Fingerprint

Dive into the research topics of '[Indoleamine 2, 3-dioxygenase activity during chemotherapy or trastuzumab therapy in patients with breast cancer].'. Together they form a unique fingerprint.

Cite this